Abate Ejigayehu G, McKenna Amanda, Yang Liu, Ball Colleen T, Kearns Ann E
Division of Endocrinology, Mayo Clinic, Jacksonville, FL, United States.
Department of Transplantation, Mayo Clinic, Jacksonville, FL, United States.
Front Endocrinol (Lausanne). 2025 Feb 20;16:1467825. doi: 10.3389/fendo.2025.1467825. eCollection 2025.
Liver transplant (LT) recipients have a substantial risk of bone loss and fracture. An individual's risk is highest before and within the first year after transplantation and returns to baseline in some patients but not all. We aim to identify risk factors for bone loss and fracture beyond the first year LT and to create a risk-scoring tool to aid clinicians in identifying those at high risk for bone loss and fracture.
We conducted a retrospective review of 264 liver transplant recipients between 2011 and 2014, who were followed in our transplant clinic for an additional five years. Clinical records were evaluated at the one-year post-LT visit and subsequently on an annual basis for up to five years.
Over a median follow-up of 3.6 years post-liver transplantation, 40 out of 264 patients experienced disease progression, defined as worsening bone mineral density (BMD), initiation of osteoporosis treatment, or a new fracture. Factors associated with BMD progression included female sex, Caucasian race, new fractures, number of acute rejection events requiring treatment, and lower dual energy X-ray absorptiometry (DXA) scores after the first year post-LT. A risk model was developed using multivariable analysis, with a risk score based on BMD categories. The concordance index was 0.771, indicating good discrimination between those who progressed and those who did not. Risk categories were defined as low (0-4 points), medium (5 points), and high (6-9 points) based on model coefficients. The probability of progression-free survival at two years post-LT was 96.7% for low-risk, 83.1% for medium-risk, and 59.1% for high-risk groups.
We developed a simple, clinically applicable risk score that predicts bone disease progression beyond the first year after LT. This tool may help guide appropriate bone health follow-up, although prospective validation is necessary.
肝移植(LT)受者有骨质流失和骨折的重大风险。个体风险在移植前及移植后的第一年内最高,部分患者的风险会恢复至基线水平,但并非所有患者都如此。我们旨在确定肝移植一年后骨质流失和骨折的风险因素,并创建一个风险评分工具,以帮助临床医生识别骨质流失和骨折的高危人群。
我们对2011年至2014年间的264例肝移植受者进行了回顾性研究,这些患者在我们的移植诊所又随访了五年。在肝移植术后一年的随访中评估临床记录,随后每年评估一次,最长为期五年。
在肝移植术后中位随访3.6年期间,264例患者中有40例出现疾病进展,定义为骨矿物质密度(BMD)恶化、开始骨质疏松治疗或出现新的骨折。与BMD进展相关的因素包括女性、白种人、新骨折、需要治疗的急性排斥事件数量以及肝移植术后第一年之后较低的双能X线吸收法(DXA)评分。使用多变量分析建立了一个风险模型,风险评分基于BMD类别。一致性指数为0.771,表明进展者与未进展者之间有良好的区分度。根据模型系数,风险类别分为低(0 - 4分)、中(5分)和高(6 - 9分)。肝移植术后两年无进展生存的概率,低风险组为96.7%,中风险组为83.1%,高风险组为59.1%。
我们开发了一种简单、临床适用的风险评分,可预测肝移植一年后骨病的进展。尽管有必要进行前瞻性验证,但该工具可能有助于指导适当的骨骼健康随访。